Skip to content
HomeMedia CenterPress releases PharmaceuticalsJanssen Human Microbiome Institute Announces Multiple Collaborations to Accelerate the Translation of Microbiome Science into Health Solutions

Janssen Human Microbiome Institute Announces Multiple Collaborations to Accelerate the Translation of Microbiome Science into Health Solutions

Agreements with DayTwo, the Weizmann Institute of Science and Caelus Health Focus on Promoting Health through Microbiome Innovation

Share Article
share to

CAMBRIDGE, M.A., Feb. 2, 2017— Janssen Research & Development, LLC (Janssen) announced today several new collaborations through its Janssen Human Microbiome Institute (JHMI) focused on advancing the discovery, development and commercialization of next-generation microbial products. The JHMI, together with the Janssen Disease Interception Accelerator (DIA), has initiated a collaboration with DayTwo Ltd. and the Weizmann Institute of Science in Rehovot, Israel, to pursue microbiome-based health solutions targeting metabolic disorders. In addition, with the scientific support of the JHMI and Bioqube Ventures, Caelus Health (Caelus) has become a portfolio company of Johnson & Johnson Innovation - JJDC, Inc. (JJDC) and one of the first companies to join the JLINX community in Beerse, Belgium, which nurtures early-stage companies by providing access to resources to grow and network across the European life science ecosystem. The agreements were facilitated by Johnson & Johnson Innovation.

“These collaborations and investments will create critical new insights to address metabolic disorders through microbiome-based diagnostics and therapeutics,” said Dirk Gevers, PhD, Global Head, Janssen Human Microbiome Institute. “By partnering with entrepreneurs, biotechs and academics and bringing innovative opportunities together with our expertise, we look to move microbiome science forward and deliver future solutions that promote individual health.”

Janssen will work together with DayTwo and Weizmann Institute of Science researchers on their first-in-class microbiome-based platform providing users with nutritional recommendations to control glucose response, with the purpose of evaluating these solutions for the effective interception of gestational diabetes mellitus (GDM), type 2 diabetes mellitus (T2DM) and metabolic syndrome-associated disorders. Further, the JHMI is engaged in a separate research collaboration with the Weizmann Institute of Science, wherein human microbiome datasets will be mined for the identification and validation of microbiome-based pharmaceutical therapies through the Weizmann Institute of Science’s robust research and analytics expertise. These efforts are based on the synergistic collaboration of Prof. Eran Segal of the Computer Science and Applied Mathematics Department, and Dr. Eran Elinav of the Immunology Department, both from the Weizmann Institute of Science.

Caelus is advancing the clinical development of pharmaceutical products based on in-human insights for the treatment of obesity-associated T2DM and cardio-metabolic complications. As a JLINX company, Caelus received an equity investment by JJDC and will have access to capabilities at JLINX. In addition, the JHMI will dedicate computational resources to Caelus to examine large, unique in-human data sets to inform the identification of future microbiome-based interventions. Dirk Gevers will join the Scientific Advisory Board of Caelus.

“We are excited about the collaborations with DayTwo and the Weizmann Institute of Science, and the JJDC investment in Caelus as they bring us one step closer to harnessing the potential of microbiome science,” said Anuk Das, Head of Scientific Innovation, Janssen Human Microbiome Institute. “DayTwo’s advanced prediction engine algorithm, the Weizmann Institute of Science’s robust research capabilities and Caelus’s portfolio of microbiota-based products provide unique opportunities to learn more about the role that the microbiome plays in disease and health.”

DayTwo, the Weizmann Institute of Science and Caelus join the Center for Microbiome Innovation at University of California San Diego and the lab of Jeremiah Faith, PhD, Assistant Professor of Genetics and Genomics Science and Clinical Immunology at the Icahn School of Medicine at Mount Sinai in the JHMI’s growing network of collaborators.

About the Janssen Pharmaceutical Companies
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at Follow us on Twitter at

# # #

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding new collaborations and investments to advance microbiome science and the development of next-generation microbial products. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaborations and investments may not be realized or may take longer to realize than expected; challenges inherent in new product development, including the uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at, or on request from Johnson & Johnson. Janssen Research & Development, LLC and Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.

Media Contact:
Brian Kenneym
Office: 215-628-7010
Mobile: 215-620-0111

Investor Contacts:
Joseph J. Wolk
Office: 732-524-1142
Lesley Fishman
Office: 732-524-3922

You are now leaving The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.